Our data herein demonstrate that combining CD40-activating immunotherapy with sunitinib treatment enhances DC activation, decreases the number of MDSCs and induces endothelial activation, leading to increased infiltration of cytotoxic T-cells into tumor tissue and reduced tumor growth (Figure 6). The gene discussed is CD40; the disease is neoplasm.